Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab + Certolizumab in rheumatoid arthritis
NCT06028438Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2023
- Primary completion
- Aug 2024
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Certolizumab + Placebo with Certolizumab + Nipocalimab (2 arms). Primary endpoint: Disease Activity Index 28 Using C-reactive Protein at 12 weeks. Started Aug 2023; status: completed.
02
Drugs
nipocalimab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06028438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06028438.